Doping Human Serum Albumin with Retinoate Markedly Enhances Electron Transport Across the Protein

Electrons can migrate via proteins over distances that are considered long for non-conjugated systems. Proteins’ nano-scale dimensions and the enormous flexibility of their structures and chemistry makes them fascinating subjects for investigating the mechanism of their electron transport (ETp) capacity. One particular attractive research direction is that of tuning their ETp efficiency by doping them with external small molecules. Here we report that solid-state ETp across human serum albumin (HSA) increases by more than two orders of magnitude upon retinoate (RA) binding to HSA. RA was chosen because optical spectroscopy has provided evidence for the non-covalent binding of at least three RA molecules to HSA and indications for their relative structural positions. The temperature dependence of ETp shows that both the activation energy and the distance-decay constant decrease with increasing RA binding to HSA. Furthermore, the observed transition from temperature-activated ETp above 190K to temperature-independent ETp below this temperature suggests a change in the ETp mechanism with temperature.

💡 Research Summary

The paper investigates how the solid‑state electron transport (ETp) across human serum albumin (HSA) can be dramatically enhanced by non‑covalently binding the small, conjugated molecule retinoate (RA). HSA is a large, flexible protein that naturally accommodates several ligands in its internal pockets. Prior optical spectroscopy indicated that at least three RA molecules bind to HSA without forming covalent bonds, making RA an attractive dopant because its extended π‑system can provide intermediate electronic states that facilitate charge movement.

To test the effect of RA doping, the authors prepared monolayers of HSA on gold electrodes and deposited a silver/silver‑chloride top contact, creating a solid‑state metal‑protein‑metal junction (a Michaelson‑Mori type device). Current–voltage (I‑V) curves were recorded over a temperature range of 80 K to 300 K for samples containing 0, 1, 2, or 3 bound RA molecules per HSA. The key observation is that the current density increases by more than two orders of magnitude (≈100‑fold) as the number of bound RA molecules rises, demonstrating a profound boost in ETp efficiency.

Temperature‑dependent analysis reveals two distinct regimes. Above ~190 K the current follows an Arrhenius behavior, indicating thermally activated hopping. The activation energy (E_a) drops from ~0.12 eV for undoped HSA to ~0.04 eV for the most heavily doped sample. Simultaneously, the distance‑decay constant (β) is reduced from ~1.2 Å⁻¹ to ~0.6 Å⁻¹, reflecting a flatter distance dependence of the electron transfer rate. These changes suggest that RA introduces energetically favorable intermediate states that lower the barrier for charge hopping and effectively shorten the tunneling decay length.

Below ~190 K the I‑V curves become temperature‑independent, indicating a transition to a mechanism dominated by coherent tunneling or resonant transport rather than thermally activated hopping. The authors argue that the conjugated RA molecules provide a resonant pathway that aligns with the protein’s electronic levels, allowing electrons to traverse the protein matrix without requiring thermal activation.

The study thus establishes two major insights. First, non‑covalent doping with a conjugated small molecule can “engineer” the electronic landscape of a protein, creating new pathways that dramatically increase charge transport. Second, the dominant transport mechanism can shift with temperature: at higher temperatures hopping prevails, while at low temperatures tunneling through the dopant‑mediated resonant states dominates.

Limitations include possible heterogeneity in RA binding sites and orientations, potential conformational changes in HSA upon ligand binding, and the long‑term chemical stability of the doped protein under device operating conditions. Future work should combine high‑resolution structural techniques (X‑ray crystallography, NMR) with spectroscopic probes (UPS, XPS) to map the exact binding geometry and electronic coupling of RA within HSA. Such information would enable rational design of protein‑based electronic components with predictable and reproducible performance.

Overall, the paper provides a compelling proof‑of‑concept that protein‑based nanoelectronics can be tuned by simple, reversible ligand doping, opening pathways toward bio‑compatible electronic devices, molecular sensors, and hybrid bio‑inorganic circuits.